The newest version of Cologuard, an at-home colon cancer screening test, results in fewer false positives that can lead to unnecessary follow-up procedures. Cologuard Plus also gives people more time ...

Exact Sciences markets Cologuard as a non-invasive, convenient test. The traditional method of testing for colorectal cancer ...

The US Food and Drug Administration (FDA) approved Exact Sciences' next-generation multitarget stool DNA (mt-sDNA) test, Cologuard Plus, for use in adults 45 or older who are at average risk for ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved ...

It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...

SHREVEPORT, La. -- No one likes to get a colonoscopy, but it's an important tool in the fight against colon cancer. There is an easier way: Cologuard is a non-invasive, effective, and affordable ...

The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...

Data demonstrate long-term impact of the Cologuard test, a powerful tool for preventing and detecting cancer The data assessed the far-reaching benefits of the first and only multi-target stool DNA ...

Q. My doctor prescribed a Cologuard test instead of a colonoscopy. No one mentioned how often Cologuard could result in false positive test results, as mine did. So, a colonoscopy was necessary after ...

An endoscopist’s knowledge of a positive Cologuard test improved colonoscopy performance, according to a Rochester, Minn.-based Mayo Clinic poster presentation at the 2016 Digestive Disease Week in ...

Exact Sciences released strong test results for its next-generation Cologuard test that pushed shares up 9% in after-hours trading. The strength of these results has made investors hopeful that ...

Jeff Smith was dumbfounded when he received a colon cancer screening kit in the mail. The 68-year-old Minnesota man hadn't asked for the Cologuard test, and his doctor hadn't mentioned anything about ...